Read more stories about
Montana Business >>

MATR Sponsor:


MATR Supporters:

Montana biotech company Inimmune receives Small Business Innovation Research Contract to discover novel treatments for seasonal allergies

October 3, 2018View for printing

Inimmune Corporation http://www.Inimmune.com , a biotechnology company located in Missoula, MT, recently received a Phase I Small Business Innovation Research (SBIR) contract in the amount of $592,624 from the National Institute for Allergy and Infectious Diseases (NIAID).

The two-year contract will help Inimmune to identify and advance new immunotherapeutics for the treatment of seasonal allergic rhinitis. The lead researcher and Principle Investigator on this award, Dr. Juhienah Khalaf, is a medicinal chemist at Inimmune. Earlier this year, Dr. Khalaf and Inimmune were awarded an SBIR Phase 1 grant to develop new immunotherapeutics for the treatment of upper respiratory tract infections.

Inimmune successfully completed the grant's milestones and has applied for a Phase II SBIR grant. Dr. Khalaf said the current Phase I SBIR Contract will "allow us to identify novel molecules, using advanced computational and medicinal chemistry approach, for the treatment of seasonal allergies." "This award is one more example of Inimmune's unwavering pursuit to discover and develop novel immunotherapies for the treatment of allergy, autoimmunity, infectious disease and cancer," stated Jay Evans, Inimmune co-founder, President, and Chief Executive Officer.

"The current Phase I SBIR award exemplifies the high quality of research at Inimmune and could help change the tide on the growing burden of allergic diseases" Hélène Bazin-Lee, Inimmune co-founder, Vice President of Early Discovery and leader of these early efforts, echoed Dr. Evans's sentiments about the usefulness of the company's discovery.

"The new immunotherapy approach developed at Inimmune for the treatment of seasonal allergies has the potential to offer rapid desensitization, better efficacy, lower side-effects and lower cost compared to currently available antigen-specific immunotherapies."

Inimmune was co-founded in 2016 by four pharmaceutical industry experts and an experienced team of researchers with the aim to harness the human immune system and create next generation immunotherapeutics. The team spent more than 20 years together working in Hamilton, MT prior to forming Inimmune in Missoula, MT.

Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) and they work in close collaboration with researchers at the University of Montana's Center for Translational Medicine to form a unique public-private partnership to foster innovation and retain high tech Montana jobs.

For more information about Inimmune please visit http://www.Inimmune.com.
No reader comments so far. Be the first to comment by clicking the button below.





Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.


E-mail this page to a friend!